Cytosurge

Cytosurge is dedicated to advancing biotechnology research, offering innovative solutions built upon its proprietary FluidFM® technology. Specializing in precise single-cell manipulation, Cytosurge is driving advancements in the understanding of cellular processes, particularly those related to cancer. The FluidFM OMNIUM platform enables single-cell extracts, or "biopsies," to be taken from living cells, facilitating live-sequencing and temporal transcriptomics analysis. Cytosurge's CellEDIT Service delivers high-quality, genetically engineered cell lines through intra-nuclear injections of CRISPR RNPs. Cytosurge is located at Saegereistrasse 25, Glattbrugg (Zurich), ZH 8152, CH.

Cytosurge's vision is to unlock novel cures by translating next-generation genetic designs into living cells, with the goal of enabling longer and healthier lives through precision gene engineering. The company focuses on implementing advanced genetically engineered cell lines that bring next-generation therapies to fruition, bridging the gap between genetic design tools and manufacturing. Cytosurge empowers genetic engineers to realize their visionary concepts.

With its innovative FluidFM® technology, Cytosurge continues to be a leader in biotechnology research. The company aims to implement advanced genetically engineered cell lines that bring next-generation therapies to fruition. We invite the management team at Cytosurge to create a customized and exclusive company showcase and product listing on our platform.